A Clinical Trial to Investigate the Safety and Efficacy of AP-Brain on Cognitive Function at Varying Dosages in Healthy Younger Adults With Self-reported Attention Problems

The goal of this clinical trial is to investigate the safety and efficacy of AP-Brain on cognitive function at varying dosages in healthy younger adults with self-reported attention problems. The main question it aims to answer is what Change from baseline to Day 56 between AP-Brain (1g, 3g, or 5g) and placebo in cognitive function, as assessed by the CNS VS Neurocognitive Index (NCI) score and complex attention. Participants will be asked to consume AP-Brain at 1 g, 3 g, or 5g, or Placebo and asked to complete memory assessment questionnaires.

Inclusion Criteria: 1. Males and females 18-39 years of age, inclusive 2. Females not of child-bearing potential, defined as those who have undergone a sterilization procedure (e.g. hysterectomy, bilateral oophorectomy, bilateral tubal ligation, complete endometrial ablation) or have been post-menopausal for at least 1 year prior to screening Or, Individuals of child-bearing potential must have a negative baseline urine pregnancy test and agree to use a medically approved method of birth control for the duration of the study. All hormonal birth control must have been in use for a minimum of three months. Acceptable methods of birth control include: * Hormonal contraceptives including oral contraceptives, hormone birth control patch (Ortho Evra), vaginal contraceptive ring (NuvaRing), injectable contraceptives (Depo-Provera, Lunelle), or hormone implant (Norplant System) * Double-barrier method * Intrauterine devices * Non-heterosexual lifestyle or agrees to use contraception if planning on changing to heterosexual partner(s) * Vasectomy of partner at least 6 months prior to screening * Abstinence and agrees to use contraception if planning on becoming sexually active 3. Individuals with self-reported focus or attention problems, as determined by QI assessment of the Adult Attention Deficit Hyperactivity Disorder Self-Report Scale (Part A) (ASRS; version 1.1) (20) 4. Agrees to avoid high sources of caffeine (e.g., supplements, tea, coffee, energy drinks), NSAIDs, and alcohol consumption for 24 hours prior to post-screening clinic visits 5. Agrees to avoid first generation anti-allergy medication for 48 hours prior to post-screening clinic visits 6. Agrees to avoid moderate-vigorous exercise 12 hours prior to post-screening clinic visits 7. Agrees to avoid travel across two or more time zones two weeks prior to any study visit 8. Agrees to maintain current lifestyle habits (diet, physical activity, medications, supplements, and sleep) as much as possible throughout the study 9. Willing and able to complete questionnaires, records, and diaries associated with the study and to complete all clinic visits 10. Provided voluntary, written, informed consent to participate in the study 11. Healthy as determined by medical history, laboratory results, and vital signs, as assessed by the QI Exclusion Criteria: 1. Individuals who are pregnant, breast feeding, or planning to become pregnant during the study 2. Allergy, sensitivity, or intolerance to the investigational product or placebo ingredients 3. Clinical diagnosis and/or prescribed treatment for ADHD (See Section 7.3.1) 4. Self-reported confirmation of any significant neuropsychological condition and/or cognitive impairment (e.g., autism spectrum disorder, schizophrenia, bipolar disorder, post-traumatic stress disorder, brain injury, neurodegenerative disease, infections, insomnia, depression, epileptic or other seizure-related disorders) that could interfere with study participation as assessed by the QI 5. Self-reported color blindness/weakness as assessed by the QI 6. Individuals who consume high caffeine daily or are addicted to caffeine at screening as assessed by the QI 7. Current employment that calls for overnight shiftwork as assessed by the QI 8. Unstable metabolic disease or chronic diseases as assessed by the QI 9. Current or history of significant diseases of the gastrointestinal tract or conditions that result in malabsorption, as assessed by the QI 10. Unstable hypertension. Treatment on a stable dose of medication for at least 3 months will be considered by the QI (See Section 7.3.1) 11. Type I diabetes 12. Type II diabetes if on insulin treatment. Type II diabetics on stable medication for at least three months and an HbA1c of \2 times/week). Occasional users will be required to washout and abstain for the duration of the study period 23. Regular use of tobacco or nicotine products in the past six months, as assessed by the QI. Occasional users will be required to washout and abstain for the duration of the study period 24. Alcohol intake average of \>2 standard drinks per day as assessed by the QI 25. Alcohol or drug abuse within the last 12 months 26. Current use of prescribed and/or OTC medications, supplements, and/or consumption of food/drinks that may impact the efficacy and/or safety of the investigational product (Sections 7.3.1 and 7.3.2) 27. Current or previous use of cognitive training programs or therapies, as assessed by the QI 28. Clinically significant abnormal laboratory results at screening as assessed by the QI 29. Blood donation 30 days prior to baseline, during the study, or a planned donation within 30 days of the last study visit 30. Participation in other clinical research studies 30 days prior to baseline, as assessed by the QI 31. Individuals who are cognitively impaired and/or unable to give informed consent 32. Any other condition or lifestyle factor, that, in the opinion of the QI, may adversely affect the participant's ability to complete the study or its measures or pose significant risk to the participant